Business Wire

THALES

Share
Innovative IoT Modem Card From Thales Makes It Easier to Build a 5G World of Trust

Thales announces the new Cinterion® MV32 modem card that makes it quicker and easier for manufacturers to build and maintain resilient, high-performance 5G devices that will transform everyday life in the years ahead. Harnessing the full potential of 5G Mobile Broadband connectivity, the new modem card is designed to be at the heart of a wide array of demanding IoT (Internet of Things) use cases, such as securely connecting enterprises, remote patient care and intelligent monitoring of renewable energy generation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220522005024/en/

Effortlessly connecting 5G networks and next-gen IoT devices

The 5G roll-out will not only bring unprecedented mobile broadband speed to billions of people worldwide. It also offers an extraordinary leap in the sheer number of devices that cellular networks can support. Connectivity will be enabled for billions more machines. As a result, 5G is laying the foundations for vast new fleets of permanently connected IoT devices that enable a more sustainable and trustworthy future for us all.

Many of these new IoT devices will be highly compact. Thales’ space-saving 5G modem card therefore represents the ideal partner for the tiny embedded SIMs (eSIMs) that are another key building block for effortless connectivity. Next-generation IoT applications will demand the always-on, ultra-high speed connectivity and exceptional reliability that characterises the new Cinterion MV32 modem card:

  • Extensively leverages Thales’ broad expertise in providing successful 5G IoT solutions that manage connectivity plans in the field, enabling seamless, go-anywhere 5G.
  • Reliably delivers superior 5G cellular performance, thanks to industry’s most advanced and optimized radio frequency design, to enable the ultra-high speed and low latency.1

Protecting against a new wave of cyber-threats

For all its benefits, the distributed, virtualized, software-based design of many 5G networks also brings with it new vulnerabilities to cyber-attack. In response, the Cinterion MV32 5G modem card embodies Thales’ unrivalled expertise and experience in bringing robust security and protection to the 5G domain:

  • Leverages Thales’ security-by-design philosophy and core expertise in robust cyber-protection – enabling dynamic protection of devices in the field and over the entire lifecycle through secure remote updates.
  • Stringently and continuously penetration-tested by independent security experts.

“We were able to be a first-mover in 5G branch networking devices, in part because Thales provided a great globally-certified solution with support to a wide variety of frequency bands. They also provided responsive support to our engineers and have been a reliable supplier even when everything else is in shortage. We look forward to deploying Thales’ next-gen 5G SA MV32 into our devices in the coming year.” Keith Chau, general manager, Peplink

“For our customers, the latest generation MV32 5G modem card represents just the right product at the right time. Manufacturers worldwide must look at 5G to enable revolutionary new IoT solutions that will touch every aspect of our lives. Our new solution makes it a cinch to embed this ultra-fast connectivity. There is no trade-off between speed, latency, reliability and cyber-protection: the compact MV32 delivers them all.” Thierry Uguen, Director Product Management IoT at Thales

1 Further technical annotations :

  • The new Cinterion 5G data card leverages the industry-standard M.2 form factor for easy plug-and-play as well as the latest 3GPP Release 16 enhanced Mobile Broadband (eMBB) standard for peak performance.
  • It consistently supports the highest levels of data throughput without overheating as a result of its sophisticated thermal design.
  • Its radio frequency design also reduces complexity and increases reliability allowing the device to tap into the highest performance grade on the field, by leveraging the latest network deployments.

To learn more, join one of our virtual launch events on May 24 at 9:00 AM or 5:00 PM.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.

PLEASE VISIT
Thales Group
Digital Identity & Security and Thales MV32 modem card
@Thalesgroup

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye